Palisade Bio, Inc. (NASDAQ:PALI) Receives $16.00 Consensus PT from Brokerages

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have earned an average rating of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $16.00.

PALI has been the topic of several recent analyst reports. B. Riley Financial initiated coverage on Palisade Bio in a research note on Friday, January 9th. They set a “buy” rating and a $7.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Palisade Bio from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a report on Monday, December 29th. Finally, Citigroup reiterated a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th.

Hedge Funds Weigh In On Palisade Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers bought a new stake in Palisade Bio in the 4th quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Palisade Bio during the 4th quarter valued at approximately $26,000. Atom Investors LP purchased a new position in shares of Palisade Bio in the fourth quarter valued at $33,000. Barclays PLC bought a new stake in Palisade Bio in the fourth quarter worth $35,000. Finally, WINTON GROUP Ltd bought a new stake in Palisade Bio in the fourth quarter worth $35,000. 11.79% of the stock is owned by institutional investors.

Palisade Bio Stock Performance

Shares of Palisade Bio stock opened at $1.60 on Friday. The company has a market capitalization of $238.40 million, a P/E ratio of -0.75 and a beta of 1.58. The company has a fifty day moving average of $1.86 and a 200 day moving average of $1.56. Palisade Bio has a fifty-two week low of $0.53 and a fifty-two week high of $2.64.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.